Best Medications for PTSD
For PTSD, selective serotonin reuptake inhibitors (SSRIs)—specifically paroxetine, sertraline, or fluoxetine—or the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine are the first-line pharmacological treatments, though psychotherapy should be prioritized over medication when possible.
First-Line Pharmacotherapy
The 2024 VA/DoD Clinical Practice Guideline provides the most authoritative guidance, making a strong recommendation for paroxetine, sertraline, or venlafaxine as first-line medications when pharmacotherapy is indicated 1. These agents have the most robust evidence base:
- Paroxetine: Demonstrated significant PTSD symptom reduction (SMD = -0.48,95% CI: -0.60 to -0.36) 2
- Sertraline: Showed efficacy (SMD = -0.23,95% CI: -0.34 to -0.11) with good tolerability 2
- Venlafaxine: Effective across multiple studies (SMD = -0.29,95% CI: -0.42 to -0.16) 2
- Fluoxetine: Also conditionally recommended with demonstrated benefit (SMD = -0.27,95% CI: -0.42 to -0.12) 2, 3
Multiple meta-analyses confirm these agents have small but statistically significant effects, with standardized mean differences around -0.23 to -0.48 compared to placebo 4.
Critical Context: Psychotherapy First
The VA/DoD guideline strongly recommends specific manualized psychotherapies over pharmacotherapy 1. Medication should be considered when:
- Psychotherapy is unavailable or declined by the patient
- Symptoms are severe enough to interfere with psychotherapy engagement
- Patient preference favors medication
- Combination treatment is clinically indicated
Second-Line Options
When first-line agents fail or are not tolerated, consider:
Atypical Antipsychotics (for augmentation or monotherapy):
- Quetiapine: Particularly effective for hyperarousal and re-experiencing symptoms (SMD = -0.49,95% CI: -0.93 to -0.04) 2
- Risperidone: May be used for PTSD-associated nightmares (SMD = -0.23,95% CI: -0.42 to -0.03) 5, 2
- Olanzapine: Shows efficacy (SMD = -0.66,95% CI: -1.19 to -0.13) but monitor metabolic side effects 2
Other agents with lower-level evidence that "may be used" for PTSD-associated nightmares include: trazodone, topiramate, gabapentin, and tricyclic antidepressants 5.
Medications to AVOID
The VA/DoD guideline strongly recommends AGAINST:
- Benzodiazepines (including clonazepam): No efficacy demonstrated and potential for harm 5, 1
- Cannabis or cannabis-derived products: Not recommended 1
- Venlafaxine for nightmares specifically: Showed no benefit over placebo for distressing dreams 5, 6
Specific Treatment for PTSD-Associated Nightmares
For nightmares specifically, the evidence has evolved:
Prazosin was previously recommended but recent large trials have downgraded this recommendation 5. The 2018 AASM position paper now states prazosin and other agents (olanzapine, risperidone, aripiprazole, clonidine, cyproheptadine, fluvoxamine, gabapentin, topiramate, trazodone) "may be used" but are not strongly recommended 5.
Image rehearsal therapy remains the strongest recommendation for nightmares over any pharmacological intervention 5.
Practical Prescribing Algorithm
- Start with an SSRI or SNRI: Begin with paroxetine 20 mg, sertraline 50 mg, fluoxetine 20 mg, or venlafaxine XR 75 mg daily
- Titrate to therapeutic doses over 4-8 weeks (e.g., sertraline up to 150-200 mg, venlafaxine up to 225 mg)
- Allow 8-12 weeks for full therapeutic response before declaring treatment failure
- If partial response: Consider dose optimization or augmentation with quetiapine (25-300 mg)
- If no response: Switch to alternative first-line agent or consider second-line options
- Monitor for: Activation symptoms early in treatment, sexual dysfunction, weight changes, and treatment adherence
Important Caveats
- The effect sizes for all medications are small (SMD typically -0.23 to -0.48), meaning many patients will need psychotherapy for optimal outcomes 4
- Combination treatment (medication plus trauma-focused psychotherapy) generally shows better outcomes than monotherapy alone 7
- Evidence is strongest for combat-related and sexual assault-related PTSD; generalizability to other trauma types is assumed but less well-studied
- Most studies maintained patients on concurrent psychotherapy during medication trials 6
- Treatment should continue for at least 12 months after symptom remission before considering discontinuation